Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Myocarditis - Overview
Myocarditis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Myocarditis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Myocarditis - Companies Involved in Therapeutics Development
Apitope Intertiol NV
Cantargia AB
Cardiol Therapeutics Inc
Dynomics Inc
Evotec SE
Swedish Orphan Biovitrum AB
Myocarditis - Drug Profiles
akinra - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATX-MYO - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAN-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
canbidiol 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
coxsackievirus B (hexavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DYN-502 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombint Peptides for Myocardial Infarction and Myocarditis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myocarditis - Dormant Projects
Myocarditis - Product Development Milestones
Featured News & Press Releases
May 10, 2021: Cantargia presents new preclinical data showing unique improvement of heart function in myocarditis using antibody CAN10
Apr 28, 2021: Cardiol Therapeutics announces first patient enrolled in LANCER, a Phase II/III outcomes trial in high-risk patients hospitalized with COVID-19
Apr 26, 2021: Cantargia presents new preclinical data on antibody CAN10 at IMMMUNOLOGY2021
Apr 12, 2021: Cardiol Therapeutics announces topline results from phase I single and multiple ascending dose clinical trial of CardiolRx
Mar 19, 2021: Cantargia reports positive preclinical safety and efficacy results in the CAN10 project
Dec 22, 2020: Cardiol Therapeutics announces completion of phase I clinical study of CardiolRx
Nov 27, 2020: BioInvent signs monoclol antibody manufacturing deal with Cantargia
Aug 26, 2020: Cardiol Therapeutics initiates Health Cada approved Phase 1 clinical study of CardiolRx
Apr 07, 2020: Cantargia provides update on development project CAN10
Apr 05, 2020: Cardiol Therapeutics receives Health Cada approval for phase 1 study of its pharmaceutically produced canbidiol (CBD) formulation
Apr 01, 2020: Cardiol Therapeutics announces study results confirm the cardioprotective role of its pharmaceutical canbidiol formulation in a model of heart failure
Dec 05, 2019: Cantargia selects CAN10 as development project in systemic sclerosis and myocarditis
Nov 25, 2019: Cardiol Therapeutics comments on the descheduling of Purisys Canbinoid ingredients by U.S. Drug Enforcement Agency
Nov 19, 2019: Cardiol Therapeutics announces clinical steering committee for phase 2 intertiol trial in Acute Myocarditis using CardiolRx 100
Oct 01, 2019: Cardiol Therapeutics announces completion of manufacturing scale-up for commercialization of CardiolRx 100
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Myocarditis, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Myocarditis, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Myocarditis - Pipeline by Apitope International NV, 2021
Myocarditis - Pipeline by Cantargia AB, 2021
Myocarditis - Pipeline by Cardiol Therapeutics Inc, 2021
Myocarditis - Pipeline by Dynomics Inc, 2021
Myocarditis - Pipeline by Evotec SE, 2021
Myocarditis - Pipeline by Swedish Orphan Biovitrum AB, 2021
Myocarditis - Dormant Projects, 2021